Metformin lowers plasma triglycerides by promoting vldl-triglyceride clearance by brown adipose tissue in mice

Diabetes

Volumn 63, Issue 3, 2014, Pages 880-891

  Geerling, Janine J ^a   Boon, Mariëtte R ^a   Van Der Zon, Gerard C ^a   Van Den Berg, Sjoerd A A ^a   Van Den Hoek, Anita M ^a,b   Lombès, Marc ^a,c   Princen, Hans M G ^a,b   Havekes, Louis M ^a,b   Rensen, Patrick C N ^a   Guigas, Bruno ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE, BROWN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; HYPOGLYCEMIC AGENTS; LIPOLYSIS; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; METFORMIN; MICE; TRIGLYCERIDES;

EID: 84894412290     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0194     Document Type: Article

References (50)

1. Goodarzi MO, Bryer-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005;7:654-665
2. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
3. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-441
4. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008;121: 149-157.e2
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998a;352:854-865
6. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-270
7. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174
8. Carling D, Thornton C, Woods A, Sanders MJ. AMP-activated protein kinase: new regulation, new roles? Biochem J 2012;445:11-27
9. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-262
10. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223-228
11. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its antidiabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348:607-614
12. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010;11:554-565
13. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011;54:3101-3110
14. Guigas B, Bertrand L, Taleux N, et al. 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 2006;55:865-874
15. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-2369
16. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642-1646
17. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010;11: 390-401
18. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256-260
19. Westerterp M, van der Hoogt CC, de Haan W, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol 2006;26:2552-2559
20. Bijland S, Pieterman EJ, Maas AC, et al. Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice. J Biol Chem 2010;285: 25168-25175
21. Bijland S, van den Berg SA, Voshol PJ, et al. CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice. J Lipid Res 2010;51:97-102
22. de Haan W, van der Hoogt CC, Westerterp M, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 2008;197:57-63
23. van der Hoorn JW, de Haan W, Berbée JF, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008; 28:2016-2022
24. Coomans CP, Geerling JJ, Guigas B, et al. Circulating insulin stimulates fatty acid retention in white adipose tissue via KATP channel activation in the central nervous system only in insulin-sensitive mice. J Lipid Res 2011;52:1712-1722
25. Teusink B, Voshol PJ, Dahlmans VE, et al. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 2003;52:614-620
26. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombès M. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998; 101:1254-1260
27. Ortega-Molina A, Efeyan A, Lopez-Guadamillas E, et al. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab 2012;15:382-394
28. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-1431
29. Pulinilkunnil T, He H, Kong D, et al. Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. J Biol Chem 2011;286: 8798-8809
30. Mulligan JD, Gonzalez AA, Stewart AM, Carey HV, Saupe KW. Upregulation of AMPK during cold exposure occurs via distinct mechanisms in brown and white adipose tissue of the mouse. J Physiol 2007;580:677-684
31. Jonker JT, Wang Y, de Haan W, et al. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes. Diabetes Care 2010;33:1625-1628
32. Xiao C, Hsieh J, Adeli K, Lewis GF. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 2011;301:E429-E446
33. Nielsen S, Karpe F. Determinants of VLDL-triglycerides production. Curr Opin Lipidol 2012;23:321-326
34. Dallinga-Thie GM, Franssen R, Mooij HL, et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010;211:1-8
35. Bartelt A, Bruns OT, Reimer R, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med 2011;17:200-205
36. Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010;464:917-921
37. Davies BS, Beigneux AP, Fong LG, Young SG. New wrinkles in lipoprotein lipase biology. Curr Opin Lipidol 2012;23:35-42
38. Festuccia WT, Blanchard PG, Deshaies Y. Control of brown adipose tissue glucose and lipid metabolism by PPARg. Front Endocrinol (Lausanne) 2011;2:84
39. Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 2002;99:15983-15987
40. Guigas B, Taleux N, Foretz M, et al. AMP-activated protein kinaseindependent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J 2007;404:499-507
41. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem 2010;47:69-84
42. Lira VA, Brown DL, Lira AK, et al. Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol 2010;588:3551-3566
43. Leverve XM, Taleux N, Favier R, et al. Cellular energy metabolism and integrated oxidative phosphorylation. In Molecular System Bioenergetics: Energy for Life. Saks V, Ed. Weinheim, WILEY-VCH Verlag GmbH & Co., 2007, p. 11-27
44. Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009;360:1509-1517
45. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Coldactivated brown adipose tissue in healthy men. N Engl J Med 2009;360: 1500-1508
46. Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009;360:1518-1525
47. Ravussin E, Galgani JE. The implication of brown adipose tissue for humans. Annu Rev Nutr 2011;31:33-47
48. Seale P, Kajimura S, Spiegelman BM. Transcriptional control of brown adipocyte development and physiological function-of mice and men. Genes Dev 2009;23:788-797
49. Ouellet V, Labbé SM, Blondin DP, et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest 2012;122:545-552
50. Labbé SM, Grenier-Larouche T, Croteau E, et al. Organ-specific dietary fatty acid uptake in humans using positron emission tomography coupled to computed tomography. Am J Physiol Endocrinol Metab 2011;300:E445-E453